梅州阴道紧缩手术的价格(梅州内切去眼袋手术) (今日更新中)

BEIJING, Jan. 26 (Xinhua) -- Chinese Premier Wen Jiabao Wednesday invited more foreign talents to continue their careers or start businesses in China, pledging better conditions for them.During a seminar with more than 20 veteran foreign experts at the Great Hall of the People a week before the Chinese New Year, Wen thanked the foreign friends for their contributions to China's achievements in 2010.Wen said 2011 is a new starting point for China's modernization, as the country implements its 12th five-year plan for economic and social development."China's development is much more associated with the world and the supply of talents than before," Wen said, adding that China will adopt a more open policy to attract overseas experts.Last year, foreign experts made more than 300,000 visits to China, according to Ji Yunshi, general director of the State Administration of Foreign Experts Affairs.

BEIJING, March 22 (Xinhua) -- China's State Food and Drug Administration (SFDA) has ordered a "serious investigation" into two kinds of bath products that reportedly gave children skin diseases.The order came after recent reports accused the body wash and lotion used by bathhouse chain Tian Po Po Xi Jiu Tang, or, literally, "Grandma Tian's Bathhouse," in southwest China's Sichuan Province of having "caused severe body damages," according to a SFDA statement released Tuesday.The bathhouse chain, with a history of some 70 years, was first established in Sichuan's capital Chengdu and was listed as a part of the city's Intangible Cultural Heritage in 2009.The licensed bathhouse claimed to use bath products developed by its own Chinese herbal medicine recipes that protected children from various skin ailments and other diseases, such as eczema, colds, and constipation.However, an unknown number of children suffered pustular psoriasis, a chronic skin irritation characterize by raised bumps, after washing at the bathhouse chain and using the two products, according to reports.Sichuan's provincial food and drug administration bureau previously deemed the two products to be "fake drugs" based on an initial investigation by the local police and food and drug authorities, the statement said.The SFDA urged local food and drug supervision departments across the country to monitor and check the two products sold by the bathhouse chain within their regions, and vowed to punish any violations of laws and regulations.

BEIJING, Feb. 10 (Xinhua) -- China's drought control authorities announced Thursday that hours of snowfall and irrigation have eased to some extent the severe drought in parts of the nation.Rapid spreading of the dry spell in the country's winter wheat producing regions has been curbed by wide-spread snowfall in the areas along the Yangtze, Huaihe and Yellow rivers and in the country's northern part on Wednesday and Thursday, the Office of State Flood Control and Drought Relief Headquarters said in a statement on its website.Drought-hit areas in Henan and Anhui, which are two major wheat-producing provinces, were reduced by 6.3 million mu (420,000 hectares) and 4.1 million mu, respectively, from Wednesday, the statement said. The agency added that irrigation also contributed to easing the effects of the drought.The statement said that as of Thursday, eight drought-hit provinces had irrigated 143 million mu of drought-affected wheat producing areas, which accounts for 52 percent of the combined winter wheat producing areas in the provinces. The eight provinces include the territories of Shandong, Henan, Hubei, Anhui, Shanxi, Shaanxi, Gansu and Jiangsu.As of 3 p.m. Thursday, the drought had affected 101.28 million mu of crops nationwide and left 2.81 million people and 2.57 million heads of livestock short of drinking water, said the statement.Cloud seeding on Wednesday and Thursday during a recent cold front, also helped alleviate drought in some regions, according to a report posted on the website of the China Meteorological Administration on Thursday.The report also said that the artificial precipitation had mitigated the shortage of moisture in the soil in parts of Henan and Anhui. The situation is expected to improve as the rain and snow continues.However, experts urged more measures from local governments to ensure winter wheat production since the current precipitation is not adequate to "completely ease the drought", the report said.

SAN FRANCISCO, April 4 (Xinhua) -- Web exploit toolkits, or " packaged" attack frameworks that can be traded online, are rapidly growing as the top cybercrime weapon due to ease of use and high success rate, a new report has found."When it comes to conducting online crime, exploit toolkits are the weapon of choice for many cyber criminals," said the "2010 Top Cyber Security Risks Report" published by Hewlett-Packard Co. (HP) on Monday.The trend started in 2006 with the release of WebAttacker, considered by many to be the first modern day web exploit toolkit, according to the report.An emerging trend ensued and soon took off, and today the Internet is subjected to hundreds of exploits originating from these toolkits."With the ever-increasing, web-based criminal activity, the number of exploit toolkits has skyrocketed and shows no signs of slowing down," the report stated.Though protecting against attacks originated with web exploit toolkits is becoming increasingly difficult, there are ways to minimize the risk of infection, said the report, noting that one of the most effective defenses is to install patches onto host systems.The report also found that while the number of attacks against known vulnerabilities continues to rise, the number of discovered vulnerabilities has plateaued in 2010."We've discovered that rather than investing resources to uncover new exploits, attackers are focused on current, unpatched vulnerabilities in web applications, social networking sites and Web 2.0 interfaces," Mike Dausin, a manager at HP Digital Vaccine Labs, said in a statement.Data from the report showed that nearly half of all reported vulnerabilities exist in web applications, and third-party plug- ins to content management systems have become the leading cause of web application vulnerabilities.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

来源：资阳报